Back to Authors

Ailawadhi, Sikander

https://orcid.org/0000-0002-8377-8111

Mayo Clinic

Mayo Clinic

Citations 383

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
Das, Saurav , Sher, Taimur , Fernandez, Andre, Parrondo, Ricardo , Parrondo, Ricardo D , Das, Saurav , Ailawadhi, Sikander , Roy, Vivek

Current Oncology | October 31, 2023 | Volume: 30 | Issue: 11 | Pages: 9627-9633

10.3390/curroncol30110697 Get It

While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis have been excluded from trials with these agents due to concerns of underlying autonomic, cardiac, and renal dysfunction, leading to potentially fatal toxicities from these therapies. In this communication, we described the outcomes of two patients with AL amyloidosis and concurrent MM with underlying cardiac and/or renal dysfunction who underwent anti-BCMA CAR T cell therapy with ide-cel or cilta-cel, received cytokine release syndrome prophylaxis, and tolerated therapy well with manageable toxicities and achieved a MRD-negative state. We described the preliminary efficacy and safety of CAR T in patients with AL amyloidosis and highlighted the importance of patient selection and medical optimization of cardiac and renal function prior to CAR T.
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?
Espinoza‐Gutarra, Manuel , Ailawadhi, Sikander

Expert Review of Hematology | October 23, 2023 | Volume: 16 | Issue: 12 | Pages: 905-910

10.1080/17474086.2023.2273851 Get It

S2714 Acute Esophageal Stricture After Bone Marrow Transplant
Pang, Songhan, Saleh, Hasan , Edgar, Mark , Pang, Maoyin , Ailawadhi, Sikander

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S1855-S1856

10.14309/01.ajg.0000960496.67368.3c Get It

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Sanchez, Larysa , Cheng, Mu, Cherepanov, Dasha , DerSarkissian, Maral , Stull, Dawn Marie, Dabora, Jonathan, Young, Melanie , Noga, Stephen J. , Pi, Selina , Banatwala, Azeem , Duh, Mei Sheng , Chari, Ajai , Chari, Ajai , Huang, Fei, Zhang, Melody , Ailawadhi, Sikander

Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 11 | Pages: 1205-1218

10.18553/jmcp.2023.23031 Get It

Superior detection rate of plasma cell FISH using FACS-FISH
Gagnon, Marie-France, Midthun, Sally M, Fangel, James A, Schuh, Cynthia M, Luoma, Ivy, Pearce, Kathryn E., Meyer, Reid G., Arribas, Mariano , Zepeda‐Mendoza, Cinthya , Xu, Xinjie , Greipp, Patricia T. , Timm, Michael, Otteson, Gregory E., Olteanu, Horatiu , Kumar, Shaji , Luoma, Ivy M, Arribas, Mariano J, Zepeda-Mendoza, Cinthya, Timm, Michael M, Shi, Min , Jevremovic, Dragan , Olteanu, Horatiu , Greipp, Patricia T , Ailawadhi, Sikander , Braggio, Esteban , Fonseca, Rafaël , Rajkumar, S. Vincent , Jevremović, Dragan , Peterson, Jess F. , Ketterling, Rhett P. , Baughn, Linda B.

American Journal of Clinical Pathology | September 2, 2023 | Volume: 161 | Issue: 1 | Pages: 60-70

10.1093/ajcp/aqad108 Get It

Abstract Objectives Fluorescence in situ hybridization (FISH) for plasma cell neoplasms (PCNs) requires plasma cell (PC) identification or purification strategies to optimize results. We compared the efficacy of cytoplasmic immunoglobulin FISH (cIg-FISH) and fluorescence-activated cell sorting FISH (FACS-FISH) in a clinical laboratory setting. Methods The FISH analysis results of 14,855 samples from individuals with a suspected PCN subjected to cytogenetic evaluation between 2019 and 2022 with cIg-FISH (n = 6917) or FACS-FISH (n = 7938) testing were analyzed. Results Fluorescence-activated cell sorting–FISH increased the detection rate of abnormalities in comparison with cIg-FISH, with abnormal results documented in 54% vs 50% of cases, respectively (P < .001). It improved the detection of IGH::CCND1 (P < .001), IGH::MAF (P < .001), IGH::MAFB (P < .001), other IGH rearrangements (P < .001), and gains/amplifications of 1q (P < .001), whereas the detection rates of IGH::FGFR3 fusions (P = .3), loss of 17p (P = .3), and other abnormalities, including hyperdiploidy (P = .5), were similar. Insufficient PC yield for FISH analysis was decreased between cIg-FISH and FACS-FISH (22% and 3% respectively, P < .001). Flow cytometry allowed establishment of ploidy status in 91% of cases. In addition, FACS-FISH decreased analysis times, workload efforts, and operating costs. Conclusions Fluorescence-activated cell sorting–FISH is an efficient PC purification strategy that affords significant improvement in diagnostic yield and decreases workflow requirements in comparison with cIg-FISH.
P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
Delforge, Michel , Patel, Krina K. , Eliason, Laurie , Dhanda, Devender , Shi, Ling , Guo, Shien, Arnulf, Bertrand , Manier, Salomon , McKiver, Mihaela Popa, Marshall, Thomas, Cavo, Michèle , Nooka, Ajay K. , Callander, Natalie S. , Giralt, Sergio , Einsele, Hermann , Ailawadhi, Sikander , Cook, Mark , Rodríguez‐Otero, Paula

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e031009e

10.1097/01.hs9.0000970524.03100.9e Get It

The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers
Ailawadhi, Sikander , Ailawadhi, Meghna, Dutta, Navnita , Parrondo, Ricardo , Sher, Taimur , Baksh, Mizba , Rasheed, Ahsan , Das, Saurav , Fernandez, A., Paulus, Aneel , Chanan‐Khan, Asher , Parrondo, Ricardo D , Fernandez, Andre J, Chanan-Khan, Asher A., Ailawadhi, Sikander , Paulus, Aneel , Das, Saurav , Roy, Vivek

Cancer Medicine | August 20, 2023 | Volume: 12 | Issue: 18 | Pages: 19013-19020

10.1002/cam4.6454 Get It

AbstractIntroductionHealth information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial‐ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization.MethodsWe undertook a patient‐reported survey among patients with lymphoid malignancies at two campuses of Mayo Clinic, Florida to explore HIT‐related disparities. Variables between Whites and non‐Whites, and non‐Whites from the two campuses were compared.ResultsThe survey was completed by 1004 respondents, with 71% whites, 27% non‐Whites (race‐ethnicity not reported by 2%). Non‐Whites included 30% responders at the main campus and 64% at an inner‐city campus. Whites were significantly older and had higher education, while non‐Whites had lesser access to a computer. Only 51% of non‐Whites were registered to use electronic medical records (EMR) as compared to 72% Whites (p < 0.001) and significantly lesser number of non‐Whites even knew that EMR existed (81% vs. 92%, p < 0.001). Encouragingly, a higher number of non‐Whites wanted to engage in EMR. Non‐Whites from the main campus were older, more educated and had more access to a computer as compared to those from the inner‐city campus. Similar disparate factors were noted among minorities from the two campuses, suggesting impact of socioeconomic backgrounds on EMR usage among non‐Whites. Linguistic barriers were more striking among inner‐city campus non‐Whites.ConclusionsNon‐Whites continue to struggle with suboptimal utilization of the healthcare system and barriers related to integration in HIT, including disparities representing socioeconomic differences. Efforts need to be made at several levels to help racial‐ethnic minorities overcome awareness, access, and linguistic barriers to HIT utilization.
P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
Manier, Salomon , Mateos, María‐Victoria , Munshi, Nikhil C. , Arnulf, Bertrand , Vij, Ravi , Broijl, Annemiek , Sborov, Douglas W. , Iida, Shinsuke , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Rodríguez‐Otero, Paula , Einsele, Hermann , Bahlis, Nizar Jacques , Ailawadhi, Sikander , Nooka, Ajay K. , Abrahamsen, Ingerid Weum , Jagannath, Sundar , Benjamin, Reuben , Gergis, Usama , Cook, Mark , Baz, Rachid

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e3385948

10.1097/01.hs9.0000970368.33859.48 Get It

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Christina, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Toomey, Kathleen, Tang, Yuexin , Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang , Ailawadhi, Sikander , Lee, Hans C. , Wagner, Lynne I. , Hardin, James W. , Jagannath, Sundar

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2 Get It

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
Popat, Rakesh , Kleinman, David , Perera, Sue, Gorsh, Boris , Mulnick, Sarah, Alicia, Oneill, Hanna, Maya, Molinari, Alexa , Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e989881c

10.1097/01.hs9.0000970648.98988.1c Get It